Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Herbert I. Hurwitz, Louis Fehrenbacher, William F. Novotny et al. · New England Journal of Medicine · 2004
BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. METHODS: Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo. The primary end point was overall survival. Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life. RESULTS: The median duration of survival was 20.3 months in the group given IFL plus bevacizumab, as compared with 15.6 months in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001). The median duration of progression-free survival was 10.6 months in the group given IFL plus bevacizumab, as compared with 6.2 months in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 percent and 34.8 percent (P=0.004). The median duration of the response was 10.4 months in the group given IFL plus bevacizumab, as compared with 7.1 months in the group given IFL plus placebo (hazard ratio for progression, 0.62; P=0.001). Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 percent vs. 2.3 percent) but was easily managed. CONCLUSIONS: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Cited by 10,971 works. doi:10.1056/nejmoa032691 Open-access PDF
Authors
- Herbert I. Hurwitz
- Louis Fehrenbacher
- William F. Novotny
- Thomas H. Cartwright
- John Daniel Hainsworth
- William J. Heim
- Jordan D. Berlin
- Ari David Baron
- Susan Griffing
- Eric B. Holmgren
- Napoleone Ferrara
- G. Fyfe
- Fairooz F. Kabbinavar
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
- The biology of VEGF and its receptors
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
- A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
- Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer
- Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
- Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy